BioSpace News Archive

ITOCO INC. (OTC Pink:ITMC) ITOCO representatives will be presenting to and attending the meeting session COP 26, Glasgow, UK, from 25 Oct 2021 to 12 Nov 2021.

Eledon Pharmaceuticals, Inc. announced their participation in the Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) which is being held virtually on October 7, 2021.

Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, announced the appointment of Matthew Kwietniak as chief commercial officer.

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the Company will present preclinical data on its progress in the development of cell therapy medicines for the treatment of cancer at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting being held in Washington, D.C., and virtually, November 10-14, 2021.

Science 37, Inc., the Operating System for today’s agile clinical trials, announced today that it has completed its previously announced business combination with LifeSci Acquisition II Corp. (NASDAQ: LSAQ) (“LifeSci”), a blank check company targeting the biopharma, medical technology, digital health and healthcare services sectors.

Global Blood Therapeutics, Inc. announced that on October 1, 2021, the compensation committee of GBT’s board of directors granted 22 new employees restricted stock units for an aggregate of 54,750 shares of the company’s common stock.

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the initiation of patient enrollment in INNATE tumor-specific expansion cohorts for both JTX-8064 monotherapy and combination therapy of JTX-8064 with its internal PD-1 inhibitor, pimivalimab.

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and liver disease, today announced that its CMO, Dr. Todd Hobbs, will present at the H.C. Wainwright 5th Annual NASH Investor Conference.

HAVN Life Sciences Inc. is pleased to announce that it has filed its final short form base shelf prospectus with the securities commissions in each of the provinces and territories of Canada and received a final receipt in respect thereof.

AffyImmune Therapeutics, Inc announced today the close of a $30 million Series A+ funding by ORI Capital (ORI).